Tirzepatide es un medicamento inyectable aprobado por la FDA para el tratamiento de la diabetes tipo 2 (bajo el nombre comercial Mounjaro) y para el manejo del peso en adultos con obesidad (IMC 30 kg/m) o sobrepeso (IMC 27 kg/m) con al menos una comorbilidad relacionada con el peso (como Zepbound)
Mass adoption
Watch the 60 Minutes CBS Report on FDA Approved Weight Loss Medicine What Happens to My Body When I Loose Weight
A GLP-1 blocker acts by inhibiting the GLP-1 receptor, which modulates the downstream inflammatory pathways linked to: cytokine production immune system activation oxidative stress inflammatory signaling in tissues such as the liver, fat cells, and gut In low doses, blocking GLP-1 receptors appears to influence the immune system without significantly interfering with glucose control which is why this approach is being studied specifically for inflammation rather than metabolic disease
Key Players in the GLP-1 Meal Replacement Market Major Global Players Huel Nestl Health Science BOOST ADM Smoothie King Herbalife Emerging and Adjacent Growth Brands Direct-to-consumer meal-format brands, pharmacy-adjacent nutrition suppliers, and clinically aligned wellness operators are likely to widen the field over the next few years
Misdiagnosing a metabolic deficiency as cognitive decline misses a critical window for corrective treatment
.webp)
